MRONJ
Also written as: MRONJ — Medication-Related Osteonecrosis of the Jaw
Medication-Related Osteonecrosis of the Jaw; exposed or prob-able necrotic bone associated with antiresorptive or antiangiogenic drug therapy, persisting for more than eight weeks.
Full Definition
MRONJ (Medication-Related Osteonecrosis of the Jaw) is the contemporary umbrella term that replaced BRONJ to reflect that jaw osteonecrosis can result not only from bisphosphonates but also from denosumab, sunitinib, bevacizumab, and other antiresorptive or antiangiogenic agents. Diagnostic criteria require exposed bone (or bone that can be probed through a fistula) for more than eight weeks, a history of the relevant medication, and no history of radiation therapy to the jaw. Editors must ensure that MRONJ is expanded on first use in clinical manuscripts and that the diagnostic criteria (particularly the eight-week threshold) are accurately stated. MRONJ must not be confused with osteoradionecrosis, which is radiation-induced.
Usage
Usage note: Expand on first use. Do not use BRONJ interchangeably; MRONJ is the current preferred term covering a broader drug class.
In Context
- "The multidisciplinary team diagnosed MRONJ (Medication-Related Osteonecrosis of the Jaw) following six months of denosumab therapy for metastatic breast cancer." — Oncology-dentistry liaison report
- "Editors must expand MRONJ at first mention and verify the eight-week duration criterion is stated." — Manuscript editorial checklist